Study details
Enrolling now
PRIMULA Lac Trial
AstraZeneca
NCT IDNCT06594068ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
16
Study length
about 1.6 years
Ages
18–130
Sex
Female only
Locations
1 site in NV
What this study is about
Researchers are testing the presence of anifrolumab in breast milk and serum among lactating women who receive anifrolumab. The trial will collect data about this for 578 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Anifrolumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
anifrolumab
Endpoints
Secondary: Maternal and Infant adverse events (AEs), Maternal serum pharmacokinetic (PK) concentrations
Body systems
Immune